<DOC>
	<DOC>NCT00421148</DOC>
	<brief_summary>The purpose of this study is: - to explore the dose-response relation of sugammadex given as a reversal agent at reappearance of T2 after 0.6 mg.kg-1 rocuronium in pediatric and adult subjects - to explore the pharmacokinetics of sugammadex in pediatric and adult subjects, and to evaluate the safety of sugammadex in pediatric and adult subjects.</brief_summary>
	<brief_title>Dose-Finding Pediatric Trial With Sugammadex (19.4.306)(P05961)(COMPLETED)</brief_title>
	<detailed_description />
	<criteria>ASA class 1 2, between the ages of 28 days and 65 years inclusive, and between the ages of 2 and 65 years inclusive for Germany and between the ages of 6 and 65 years inclusive for Finland Scheduled for general anesthesia with an anticipated duration of anesthesia of at least 60 minutes, without further need for muscle relaxation other than one single dose of 0.6 mg.kg1 rocuronium Scheduled for surgical procedures in the supine position Subjects who, and/or whose parent(s) or legal guardian(s) have given written informed consent [or appropriate assent, if applicable] Known or suspected neuromuscular disorders impairing NMB and/or significant renal dysfunction, in Germany creatinine and blood urea nitrogen outside local reference ranges Known or suspected to have a (family) history of malignant hyperthermia Known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia Use of medication expected to interfere with the rocuronium given in this trial, based on the dose and the time of administration Pregnancy Childbearing potential not using any of the following methods of birth control: condom or diaphragm with spermicide, vasectomized partner ( &gt; 6 months), IUD, abstinence Breast feeding Prior participation in trial 19.4.306 Participation in another clinical trial, not preapproved by NV Organon, within 30 days of entering into trial 19.4.306</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>